View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
TREAS/IRS | RIN: 1545-BQ92 | Publication ID: Spring 2024 |
Title: ●Sec. 5000D Excise Tax | |
Abstract:
This regulatory action prescribes rules related to the tax imposed by 26 U.S.C. 5000D. Section 5000D(a) imposes a tax on the sale of a designated drug by the manufacturer, producer, or importer” of such drug during a day described in section 5000D(b). The section 5000D tax arises in relation to milestones of a prescription drug price negotiation program administered by the Centers for Medicare and Medicaid Services (CMS) (the Program). See sections 119198 of the Social Security Act (SSA). Under the Program, CMS selects a small number of single-source drugs for price negotiation, SSA section 1192(a); authorized generics (meaning, roughly, drugs made under licensing agreements) are treated as single-source drugs, SSA section 1192(e)(2)(A). |
|
Agency: Department of the Treasury(TREAS) | Priority: Substantive, Nonsignificant |
RIN Status: First time published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: Undetermined | Unfunded Mandates: Undetermined |
CFR Citation: 26 CFR 47.5000D-0 through -4 | |
Legal Authority: 26 U.S.C. 5000D 26 U.S.C. 7805 |
Legal Deadline:
None |
||||||
Timetable:
|
Additional Information: Drafting attorney: James Williford III, (202) 317-3225 Reviewing attorney: Michael Beker, (202) 317-5258 Treasury attorney: Vivek Chandrasekhar, (202) 622-1082 and Elisabeth Shellan (202) 622-1727 CC:PSI REG-115560-23 | |
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: Undetermined |
Small Entities Affected: No | Federalism: Undetermined |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: James S. Williford Attorney Department of the Treasury Internal Revenue Service 1111 Constitution Avenue NW, Room 4527, Washington, DC 20224 Phone:202 317-3225 Email: james.w.williford@irscounsel.treas.gov |